In the last 12 months, insiders at Mereo BioPharma neither bought nor sold shares on the open market.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Denise Scots-Knight | Chief Executive Officer | 808,921 | 0 | 808,921 | 63.0% | 16 Sep, 2024 |
| 2 | Charles Sermon | General Counsel | 219,061 | 0 | 219,061 | 17.1% | 16 Sep, 2024 |
| 3 | Christine Ann Fox | Chief Financial Officer | 89,285 | 0 | 89,285 | 7.0% | 16 Sep, 2024 |
| 4 | John A. Lewicki | Chief Scientific Officer | 78,630 | 0 | 78,630 | 6.1% | 16 Sep, 2024 |
| 5 | Alexandra Hughes-Wilson | Officer | 50,475 | 0 | 50,475 | 3.9% | 16 Sep, 2024 |
| 6 | Michael S Wyzga | Director | 25,050 | 0 | 25,050 | 2.0% | 17 Jun, 2024 |
| 7 | Jeremy Bender | Director | 0 | 12,550 | 12,550 | 1.0% | 17 Jun, 2024 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 26 Feb, 2026 | Michael S Wyzga | Director | Acquired A | 66,000 | $0.00 | $0 | 66,000 | Direct |
| 26 Feb, 2026 | Annalisa Jenkins | Director | Acquired A | 66,000 | $0.00 | $0 | 66,000 | Direct |
| 26 Feb, 2026 | Deepika Pakianathan | Director | Acquired A | 66,000 | $0.00 | $0 | 66,000 | Direct |
| 26 Feb, 2026 | Anders Ekblom | Director | Acquired A | 66,000 | $0.00 | $0 | 66,000 | Direct |
| 26 Feb, 2026 | Marc J Yoskowitz | Director | Acquired A | 66,000 | $0.00 | $0 | 66,000 | Direct |
| 26 Feb, 2026 | Jeremy Bender | Director | Acquired A | 66,000 | $0.00 | $0 | 66,000 | Direct |
| 26 Feb, 2026 | Pierre Jacquet | Director | Acquired A | 66,000 | $0.00 | $0 | 66,000 | Direct |
| 26 Feb, 2026 | Daniel Shames | Director | Acquired A | 66,000 | $0.00 | $0 | 66,000 | Direct |
| 26 Feb, 2026 | Jeremy Bender | Director | Acquired A | 117,533 | — | — | 117,533 | Direct |
| 26 Feb, 2026 | Annalisa Jenkins | Director | Acquired A | 106,848 | — | — | 106,848 | Direct |
| 26 Feb, 2026 | Marc J Yoskowitz | Director | Acquired A | 96,163 | — | — | 96,163 | Direct |
| 26 Feb, 2026 | Pierre Jacquet | Director | Acquired A | 106,848 | — | — | 106,848 | Direct |
| 26 Feb, 2026 | Daniel Shames | Director | Acquired A | 96,163 | — | — | 96,163 | Direct |
| 26 Feb, 2026 | Anders Ekblom | Director | Acquired A | 133,560 | — | — | 133,560 | Direct |
| 01 Feb, 2026 | Denise Scots-Knight | Chief Executive Officer | Acquired A | 1,035,000 | $0.00 | $0 | 1,035,000 | Direct |
| 01 Feb, 2026 | John A. Lewicki | Chief Scientific Officer | Acquired A | 139,913 | $0.00 | $0 | 139,913 | Direct |
| 01 Feb, 2026 | Charles Sermon | General Counsel | Acquired A | 315,750 | $0.00 | $0 | 315,750 | Direct |
| 01 Feb, 2026 | Christine Ann Fox | Chief Financial Officer | Acquired A | 315,750 | $0.00 | $0 | 315,750 | Direct |
| 01 Feb, 2026 | Alexandra Hughes-Wilson | Officer | Acquired A | 183,750 | $0.00 | $0 | 183,750 | Direct |
| 01 Feb, 2026 | John A. Lewicki | Chief Scientific Officer | Acquired A | 46,637 | $0.00 | $0 | 46,637 | Direct |